Tech Company Financing Transactions
Infinimmune Funding Round
Infinimmune closed a $75 million Series A funding round on 8/12/2026. Backers included Playground Global, Regeneron Pharmaceuticals and Civilization Ventures.
Transaction Overview
Company Name
Announced On
8/12/2026
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate clinical development of its two lead programs in atopic dermatitis, support advancement of additional programs leveraging human-first biology, and enable continued deployment of its Anthrobody discovery platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Francisco, CA Undisclosed
USA
San Francisco, CA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
We screen human samples containing B cells, which encode antibodies. We use single cell genomics to read antibody sequences from single B cells. We write antibodies and create superior drug candidates.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wyatt McDonnell
Founder
Mike Gibbons
Founder
Lance Hepler
Founder
David Jaffe
Founder
Katie Pfeiffer
Browse more venture capital transactions:
Prev: 8/12/2026: CodeRabbit venture capital transaction
Next: 8/12/2026: Skan venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs